CLI. Two-year mortality in the BASIL trial was 26.8% (7) . In the Swedish national experience, the mortality rate was 27.7 and 13.4 per hundred person-years for those with and without diabetes, respectively (8) .
Thus, the difficulty in determining who will benefit from a surgical or endovascular procedure rests less on the procedural morbidity and mortality than on the expectation of survival long enough to accomplish recovery and enjoy its effects.
It is in this aspect that Soga et al. (9) , in this issue of JACC: Cardiovascular Interventions, have improved the process of patient selection. The authors retrospectively evaluated 995 patients who were followed for more than 2 years after endovascular revascularization for CLI. The mortality rate, as expected, was high at 41%, and cardiovascular death was the most common cause of death. Using this cohort, the au- 
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